SG11202107050RA - Treating iron deficiency in subjects at risk of cardiovascular adverse events and iron for the management of atrial fibrillation - Google Patents
Treating iron deficiency in subjects at risk of cardiovascular adverse events and iron for the management of atrial fibrillationInfo
- Publication number
- SG11202107050RA SG11202107050RA SG11202107050RA SG11202107050RA SG11202107050RA SG 11202107050R A SG11202107050R A SG 11202107050RA SG 11202107050R A SG11202107050R A SG 11202107050RA SG 11202107050R A SG11202107050R A SG 11202107050RA SG 11202107050R A SG11202107050R A SG 11202107050RA
- Authority
- SG
- Singapore
- Prior art keywords
- iron
- subjects
- risk
- management
- adverse events
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1900371.4A GB201900371D0 (en) | 2019-01-10 | 2019-01-10 | Iron in a trial fibrillation |
US201962803455P | 2019-02-09 | 2019-02-09 | |
EP19179820 | 2019-06-12 | ||
PCT/IB2020/051033 WO2020144667A1 (en) | 2019-01-10 | 2020-02-10 | Treating iron deficiency in subjects at risk of cardiovascular adverse events and iron for the management of atrial fibrillation |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202107050RA true SG11202107050RA (en) | 2021-07-29 |
Family
ID=71520720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202107050RA SG11202107050RA (en) | 2019-01-10 | 2020-02-10 | Treating iron deficiency in subjects at risk of cardiovascular adverse events and iron for the management of atrial fibrillation |
Country Status (7)
Country | Link |
---|---|
US (1) | US20220062331A1 (en) |
EP (1) | EP3908289A1 (en) |
AU (1) | AU2020206021A1 (en) |
CA (1) | CA3125413A1 (en) |
GB (1) | GB2595135B (en) |
SG (1) | SG11202107050RA (en) |
WO (1) | WO2020144667A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2022323733A1 (en) * | 2021-08-03 | 2024-02-29 | Pharmacosmos Holding A/S | Iron complex compounds for subcutaneous use in therapy of iron deficiency in companion animals |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2756580A1 (en) * | 2009-03-25 | 2010-09-30 | Hans Andreasen | A stable iron oligosaccharide compound |
EP2537866A1 (en) | 2011-06-21 | 2012-12-26 | Serumwerk Bernburg AG | Hydroxyethyl starch derivatives, method for manufacturing the same and therapeutical uses thereof |
EP2822574A4 (en) | 2012-03-05 | 2016-01-27 | Luitpold Pharm Inc | Methods for modulation of phosphorus and fgf23 |
KR20200044030A (en) | 2017-09-11 | 2020-04-28 | 파르마코스모스 홀딩 에이/에스 | Therapeutic iron complex |
-
2020
- 2020-02-10 US US17/421,481 patent/US20220062331A1/en active Pending
- 2020-02-10 AU AU2020206021A patent/AU2020206021A1/en active Pending
- 2020-02-10 WO PCT/IB2020/051033 patent/WO2020144667A1/en unknown
- 2020-02-10 GB GB2111459.0A patent/GB2595135B/en active Active
- 2020-02-10 SG SG11202107050RA patent/SG11202107050RA/en unknown
- 2020-02-10 EP EP20705259.8A patent/EP3908289A1/en active Pending
- 2020-02-10 CA CA3125413A patent/CA3125413A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
GB2595135A (en) | 2021-11-17 |
AU2020206021A1 (en) | 2021-07-22 |
US20220062331A1 (en) | 2022-03-03 |
GB2595135B (en) | 2022-10-26 |
EP3908289A1 (en) | 2021-11-17 |
CA3125413A1 (en) | 2020-07-16 |
WO2020144667A1 (en) | 2020-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL292821A (en) | Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter | |
ZA202007993B (en) | Methods of reducing the risk of cardiovascular events in a subject | |
SG11202104158SA (en) | Composition and method for treating the lungs | |
EP3579827A4 (en) | Triplet combination formulations and methods of treating or reducing the risk of cardiovascular disease | |
IL282375A (en) | 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating α-synucleinopathies, tauopathies, and other disorders | |
GB2595135B (en) | Treating iron deficiency in subjects at risk of cardiovascular adverse events and iron for the management of atrial fibrillation | |
SG11202112515RA (en) | Methods and compositions for treating liver disorders | |
EP3891274C0 (en) | Compositions and methods for treating ornithine transcarbamylase deficiency | |
SG11202012426WA (en) | Treatment of stage iii nsclc and mitigation of pathological conditions associated with the treatment | |
IL304736A (en) | Binding agents and methods of using the same | |
EP3541185C0 (en) | Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension | |
IL288843A (en) | Treating iron deficiency in subjects at risk of cardiovascular adverse events | |
ZA202007183B (en) | Compositions and methods for treating the eye | |
SG11202111509PA (en) | Methods of assessing and treating hepatic encephalopathy | |
GB201918404D0 (en) | Compounds and their use for the treatment of aplha1-antitrypsin deficiency | |
EP3781262A4 (en) | Compositions and methods for treating cardiovascular disease in selected patients | |
ZA202107513B (en) | Compounds and compositions comprising the same for treating hypertension or heart failure | |
IL287955A (en) | Use of co-crystals of tramadol and celecoxib for treating pain while reducing the abuse liability of tramadol | |
EP3496742A4 (en) | Peptibodies, compositions thereof, and methods of treating atrial fibrillation | |
ZA202108822B (en) | System and process for determining in-line the characteristics of spent balls and pieces of same | |
IL281501A (en) | Compositions and methods for treating cellulite | |
EP3691635A4 (en) | Methods and compositions involving bucindolol for the treatment of atrial fibrillation | |
EP3421025A4 (en) | Method for treating and preventing peripheral circulation disorders and inversion table for the implementation thereof | |
IL312523A (en) | Methods for treating cardiovascular conditions and methods of increasing the efficiency of cardiac metabolism | |
GB201903259D0 (en) | Systems and methods for treating cardiac arrhythmia |